Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Clene Inc. (CLNN : NSDQ)

• Company Description    Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I Limited, is based in SALT LAKE CITY. Number of Employees: 79

• Price / Volume Information    Yesterday's Closing Price: $6.70 Daily Weekly Monthly 20 Day Moving Average: 1,351,247 shares Shares Outstanding: 12.78 (millions) Market Capitalization: $85.61 (millions) Beta: 0.89 52 Week High: $13.50 52 Week Low: $2.28 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.94% 3.62% 12 Week 25.00% 15.56% Year To Date 14.14% 6.66%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6550 SOUTH MILLROCK DRIVE SUITE G50 - SALT LAKE CITY,UT 84121 USA ph: 801-676-9695 fax: - kgardner@lifesciadvisors.com https://clene.com

• General Corporate Information    Officers Robert Etherington - President; Chief Executive Officer and Director David J. Matlin - rman of the Board Morgan R. Brown - Chief Financial Officer Arjun Desai - Director Jonathon T. Gay - Director Peer Information Clene Inc. (CORR.) Clene Inc. (RSPI) Clene Inc. (CGXP) Clene Inc. (BGEN) Clene Inc. (GTBP) Clene Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 185634201 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 12.78 Most Recent Split Date: 7.00 (0.05:1) Beta: 0.89 Market Capitalization: $85.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.37 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.58 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 638.90 EPS Growth vs. Year Ago Period: 38.00% vs. Previous Quarter: 64.77% Sales Growth vs. Year Ago Period: -81.48% vs. Previous Quarter: -80.52% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - -137.98 12/31/25 - -135.77 09/30/25 - -140.71 Current Ratio 03/31/26 - 1.94 12/31/25 - 0.83 09/30/25 - 1.53 Quick Ratio 03/31/26 - 1.93 12/31/25 - 0.83 09/30/25 - 1.52 Operating Margin 03/31/26 - -21,683.58 12/31/25 - -14,915.00 09/30/25 - -15,959.35 Net Margin 03/31/26 - -25,009.70 12/31/25 - -13,086.50 09/30/25 - -14,250.47 Pre-Tax Margin 03/31/26 - -25,009.70 12/31/25 - -13,086.50 09/30/25 - -14,250.47 Book Value 03/31/26 - -1.47 12/31/25 - -1.62 09/30/25 - -1.23 Inventory Turnover 03/31/26 - 0.40 12/31/25 - 0.80 09/30/25 - 0.62 Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©